Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk

David Burr, Tamim Diab, Andrew Koivunemi, Mark Koivunemi, Matthew Allen

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Bisphosphonate (BP) treatment used to prevent bone loss in postmenopausal osteoporosis has recently been implicated in an apparent increase in subtrochanteric femoral fractures. Previous work showed that BPs can reduce the energy to fracture of cancellous bone, but limited data exist on material-level mechanical properties of compact bone from the long bones. This study examined intrinsic mechanical properties of the femoral diaphysis of a canine model treated for 1 or 3 years with alendronate at two different doses. Seventy-two dogs were treated orally with 0.2 mg/kg/day alendronate or 1.0 mg/kg/day alendronate; a control group was administered saline. Prismatic beam specimens were tested in four-point bending under displacement control, and the intrinsic mechanical properties were calculated. No significant differences were found among groups in any mechanical property at either 1 or 3 years of treatment. We conclude that the material properties of the femoral diaphysis are not degraded following 1 to 3 years treatment with alendronate, even at high doses. Longer periods of treatment have not been studied using clinical doses of alendronate, but such studies need to be carried out to confirm a lack of effect of alendronate on mechanical properties of cortical bone in the subtrochanteric region of the femur.

Original languageEnglish
Pages (from-to)1288-1292
Number of pages5
JournalJournal of Orthopaedic Research
Volume27
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Alendronate
Femoral Fractures
Hip Fractures
Thigh
Canidae
Diaphyses
Bone and Bones
Postmenopausal Osteoporosis
Diphosphonates
Femur
Dogs
Control Groups

Keywords

  • Biomechanics
  • Bisphosphonates
  • Femur
  • Subtrochanteric fractures

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model : Implications for subtrochanteric femoral fracture risk. / Burr, David; Diab, Tamim; Koivunemi, Andrew; Koivunemi, Mark; Allen, Matthew.

In: Journal of Orthopaedic Research, Vol. 27, No. 10, 10.2009, p. 1288-1292.

Research output: Contribution to journalArticle

@article{413cf95e93744a6e84fe97cbca25a7ba,
title = "Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk",
abstract = "Bisphosphonate (BP) treatment used to prevent bone loss in postmenopausal osteoporosis has recently been implicated in an apparent increase in subtrochanteric femoral fractures. Previous work showed that BPs can reduce the energy to fracture of cancellous bone, but limited data exist on material-level mechanical properties of compact bone from the long bones. This study examined intrinsic mechanical properties of the femoral diaphysis of a canine model treated for 1 or 3 years with alendronate at two different doses. Seventy-two dogs were treated orally with 0.2 mg/kg/day alendronate or 1.0 mg/kg/day alendronate; a control group was administered saline. Prismatic beam specimens were tested in four-point bending under displacement control, and the intrinsic mechanical properties were calculated. No significant differences were found among groups in any mechanical property at either 1 or 3 years of treatment. We conclude that the material properties of the femoral diaphysis are not degraded following 1 to 3 years treatment with alendronate, even at high doses. Longer periods of treatment have not been studied using clinical doses of alendronate, but such studies need to be carried out to confirm a lack of effect of alendronate on mechanical properties of cortical bone in the subtrochanteric region of the femur.",
keywords = "Biomechanics, Bisphosphonates, Femur, Subtrochanteric fractures",
author = "David Burr and Tamim Diab and Andrew Koivunemi and Mark Koivunemi and Matthew Allen",
year = "2009",
month = "10",
doi = "10.1002/jor.20895",
language = "English",
volume = "27",
pages = "1288--1292",
journal = "Journal of Orthopaedic Research",
issn = "0736-0266",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model

T2 - Implications for subtrochanteric femoral fracture risk

AU - Burr, David

AU - Diab, Tamim

AU - Koivunemi, Andrew

AU - Koivunemi, Mark

AU - Allen, Matthew

PY - 2009/10

Y1 - 2009/10

N2 - Bisphosphonate (BP) treatment used to prevent bone loss in postmenopausal osteoporosis has recently been implicated in an apparent increase in subtrochanteric femoral fractures. Previous work showed that BPs can reduce the energy to fracture of cancellous bone, but limited data exist on material-level mechanical properties of compact bone from the long bones. This study examined intrinsic mechanical properties of the femoral diaphysis of a canine model treated for 1 or 3 years with alendronate at two different doses. Seventy-two dogs were treated orally with 0.2 mg/kg/day alendronate or 1.0 mg/kg/day alendronate; a control group was administered saline. Prismatic beam specimens were tested in four-point bending under displacement control, and the intrinsic mechanical properties were calculated. No significant differences were found among groups in any mechanical property at either 1 or 3 years of treatment. We conclude that the material properties of the femoral diaphysis are not degraded following 1 to 3 years treatment with alendronate, even at high doses. Longer periods of treatment have not been studied using clinical doses of alendronate, but such studies need to be carried out to confirm a lack of effect of alendronate on mechanical properties of cortical bone in the subtrochanteric region of the femur.

AB - Bisphosphonate (BP) treatment used to prevent bone loss in postmenopausal osteoporosis has recently been implicated in an apparent increase in subtrochanteric femoral fractures. Previous work showed that BPs can reduce the energy to fracture of cancellous bone, but limited data exist on material-level mechanical properties of compact bone from the long bones. This study examined intrinsic mechanical properties of the femoral diaphysis of a canine model treated for 1 or 3 years with alendronate at two different doses. Seventy-two dogs were treated orally with 0.2 mg/kg/day alendronate or 1.0 mg/kg/day alendronate; a control group was administered saline. Prismatic beam specimens were tested in four-point bending under displacement control, and the intrinsic mechanical properties were calculated. No significant differences were found among groups in any mechanical property at either 1 or 3 years of treatment. We conclude that the material properties of the femoral diaphysis are not degraded following 1 to 3 years treatment with alendronate, even at high doses. Longer periods of treatment have not been studied using clinical doses of alendronate, but such studies need to be carried out to confirm a lack of effect of alendronate on mechanical properties of cortical bone in the subtrochanteric region of the femur.

KW - Biomechanics

KW - Bisphosphonates

KW - Femur

KW - Subtrochanteric fractures

UR - http://www.scopus.com/inward/record.url?scp=70349218082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349218082&partnerID=8YFLogxK

U2 - 10.1002/jor.20895

DO - 10.1002/jor.20895

M3 - Article

C2 - 19396816

AN - SCOPUS:70349218082

VL - 27

SP - 1288

EP - 1292

JO - Journal of Orthopaedic Research

JF - Journal of Orthopaedic Research

SN - 0736-0266

IS - 10

ER -